Investing
The company will be headed by Verily's cofounder Tom Stanis.
This comes roughly a year after the company raised $113 million in Series B funding.
The company currently has three prescription digital therapeutics available on the market.
Also: Stanford University spinout Deepcell lands $20 million in funding and Folx raises $4.4 million.
The company projects that sales of its testing kits will triple by the end of 2020.
The company also announced that it is expanding into the Asia Pacific region.
The funding will be used to expand its new prescription therapeutic under the German Digital Healthcare Act.
The company plans to use the new money to expand.
This is Olive's third raise in 2020 alone, and now values the AI company at $1.5 billion.
The company plans to use the funds to propel commercialization efforts and add new technology capabilities.